Skip to main content

Table 3 PET/MRI response categorisation

From: Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

Category/Parameter Complete Response (CR) Partial Response (PR) Stable Disease (SD) Progressive Disease (PD)
18F FDG PET SULpeak Resolution of target lesion activity: activity less than mean liver activity & indistinguishable from background blood-pool levels. Disappearance of all other lesions to background blood-pool levels. ≥30% reduction of target lesion SULpeak. Absolute decrease ≥0.8 SUL units.
Measurement is commonly in same lesion as baseline but can be another lesion if this is now the most active lesion after treatment.
Does not fulfil criteria for response or progression >30% increase of target lesion SULpeak. New 18F FDG avid lesions.
DW-MRI ADC50–900 Resolution of DWI signal Persistence of DWI signal; >30% increase in ADCmean Does not fulfil criteria for response or progression Persistence of DWI signal; >25% reduction in ADCmean
DCE-MRI
SInormalised
Resolution of enhancement Persistence of enhancement; >40% decrease in SInorm Does not fulfil criteria for response or progression Persistence of enhancement; >40% increase in SInorm